Both Subutex and Suboxone treat opioid use disorder with the same core ingredient, buprenorphine, and differ mainly in whether they contain naloxone. Here at Porch Light Health, we know that choosing between them can feel overwhelming. We work with people every day to match the right buprenorphine therapy to their history.
In this guide, we compare the two on safety, misuse risk, effectiveness, pregnancy and liver considerations, cost, and 2026 access rules. We’ve written it for anyone weighing buprenorphine treatment, and for the family members helping them.
Subutex and Suboxone are prescription buprenorphine products used to treat opioid use disorder. The practical difference comes down to one ingredient: naloxone. That single addition shapes how clinicians prescribe each one.
As a team that treats opioid use disorder every day, we can help you understand which formulation fits your history. The core difference comes down to the active ingredients:
Both names started as brands. Today, generic buprenorphine and generic buprenorphine/naloxone are widely available for outpatient medication for addiction treatment (MAT), which has lowered cost and improved access.
| Feature | Subutex (Buprenorphine) | Suboxone (Buprenorphine + Naloxone) |
| Active ingredients | Buprenorphine only | Buprenorphine + naloxone |
| Purpose of second ingredient | None | Naloxone deters injection misuse |
| Common form | Sublingual tablet | Sublingual film or tablet |
| Brand status | Brand discontinued 2011 | Brand available; generics common |
| Typical use | Naloxone allergy, select pregnancy cases, severe liver disease | Default for most outpatient OUD treatment |
| Misuse deterrent | Lower | Higher (naloxone precipitates withdrawal if injected) |
Understanding the naloxone difference clarifies the safety and prescribing tradeoffs. It also leads naturally into how buprenorphine works at opioid receptors.
Buprenorphine is a partial mu opioid receptor agonist. It relieves withdrawal and cravings while producing a ceiling effect on respiratory depression, which is why it is a first-line medication for opioid use disorder.
Because buprenorphine activates receptors only partially, escalating doses reach a point beyond which opioid effects plateau. That ceiling lowers the risk of the dangerous breathing slowdown seen with full agonists like heroin, fentanyl, or prescription opioids such as oxycodone.
Naloxone plays a different role. It is an opioid antagonist added to Suboxone to block opioid effects if the product is injected, which helps reduce intravenous diversion. Because naloxone has very low sublingual absorption, it stays largely inactive when Suboxone is taken as prescribed under the tongue.
There is one exception worth knowing. In severe liver disease, naloxone exposure can rise and become clinically relevant, which is why the FDA’s Suboxone labeling advises caution in moderate to severe hepatic impairment.
The brand Subutex was discontinued in 2011. That does not mean buprenorphine-only is gone.
Generic buprenorphine tablets remain available, and generic buprenorphine/naloxone has been on the market since the FDA approved it in 2018. In practice, clinicians prescribe the generic monoproduct when a patient needs buprenorphine without naloxone.
Generic versions generally cost less than branded products, and that lower price often reduces out-of-pocket cost and improves access for many people.
Some states and insurers place restrictions on buprenorphine-only prescriptions, such as in pregnancy or under particular state rules. Verify the rules and formulary requirements that apply to you with your clinician when choosing between the two.
Both products contain buprenorphine to reduce overdose risk and cravings, and both are considered effective. Suboxone is the more commonly prescribed of the two for outpatient treatment, because the added naloxone lowers injection-misuse and diversion risk in a way that aligns with payer and regulatory expectations.
Subutex (buprenorphine-only) may be chosen when naloxone is contraindicated, including:
For a safe plan, discuss these factors with a clinician:
Our addiction psychiatry and medical team can match the formulation to your situation and ongoing monitoring needs.
Buprenorphine alone (Subutex) and buprenorphine plus naloxone (Suboxone) produce comparable benefits for staying in care, reducing illicit opioid use, and lowering overdose risk. Randomized trials and systematic reviews consistently show buprenorphine improves retention and reduces opioid use compared with no medication.
Adding naloxone mainly reduces diversion rather than changing clinical effectiveness. In other words, the choice between them is usually about safety, misuse risk, and individual factors, not about whether one works better.
Outcomes do improve with good medication adherence, the right formulation, and access to counseling. Extended-release options and integrated behavioral health support stronger long-term retention. If you’re weighing a long-acting option, our guide on how Sublocade compares with Suboxone breaks down the differences.
Prenatal buprenorphine exposure can cause neonatal opioid withdrawal. Even so, evidence indicates exposed newborns often have shorter hospital stays than those exposed to methadone, and a well-supervised start helps maintain these gains.
Buprenorphine induction requires careful timing. Because buprenorphine binds opioid receptors tightly and only partially activates them, taking it too soon after other opioids can displace them and trigger precipitated withdrawal.
To lower that risk, clinicians wait until you are in objective withdrawal before the first dose. They commonly use the Clinical Opiate Withdrawal Scale (COWS) and aim for at least moderate withdrawal, often a score of 11–12 or higher, consistent with SAMHSA and ASAM guidance.
The required wait depends on the opioid you last used, as shown below. Coming off illicit fentanyl is especially tricky because it can linger in body tissue, so clinicians increasingly use microdosing (the Bernese method) to start buprenorphine while you continue a full agonist.
| Last Opioid Used | Typical Wait Before First Dose | Notes |
| Short-acting (heroin, oxycodone, hydrocodone) | 12–24 hours | Start in objective withdrawal (COWS) |
| Long-acting (e.g., extended-release) | 24–48 hours | Longer half-life delays withdrawal onset |
| Methadone | 48–72 hours or more | Taper and timing managed by a clinician |
| Suspected fentanyl | Often >24 hours; consider microdosing | Tissue accumulation raises precipitated-withdrawal risk |
Typical first dosing starts at 2–4 mg sublingually, repeated under observation up to roughly 8–16 mg on day one. Maintenance commonly falls between 8 and 24 mg per day, and your clinician individualizes it.
Telemedicine can safely guide a home induction when you and your clinician use real-time COWS checks and an emergency plan. Seek urgent care or contact your provider immediately if you develop:
How you get buprenorphine has changed dramatically, and the shift directly affects how quickly you can start either Subutex or Suboxone. For years, prescribing was gated by the DATA 2000 “X-waiver,” a special federal credential most clinicians never obtained, which kept the number of buprenorphine prescribers small and waitlists long.
That barrier is gone. The SAMHSA-documented Mainstreaming Addiction Treatment (MAT) Act, signed into law in late 2022, eliminated the X-waiver entirely. Now any clinician with a standard DEA registration that includes Schedule III authority can prescribe buprenorphine for opioid use disorder.
The practical effect is large. Federal estimates suggest the change expanded the pool of potential prescribers from roughly 130,000 to about 1.8 million, which means more clinics, shorter waits, and more places to start treatment close to home.
Telehealth access has expanded in parallel. The DEA and the Department of Health and Human Services have extended COVID-era telemedicine flexibilities for controlled substances, including buprenorphine, through December 31, 2026. Under these rules, an eligible clinician can start buprenorphine after an audio-video visit, and audio-only (phone) visits are permitted for buprenorphine when video is not available.
A 2025 DEA framework specific to buprenorphine adds another option. A clinician can prescribe via telemedicine for up to six months before an in-person visit is required, with a check of the state prescription drug monitoring program (PDMP) before each prescription.
What this means for you is concrete. You may be able to begin treatment the same week through a virtual visit if you:
Our telehealth MAT services use video and, where appropriate, phone-based visits to start and continue buprenorphine, paired with the monitoring these federal rules expect. Telehealth doesn’t replace clinical judgment, though. A clinician still confirms your withdrawal status, reviews your history and PDMP data, and arranges follow-up, lab work, and in-person care when it’s needed.
Subutex usually comes as a sublingual tablet, while Suboxone is a sublingual film or tablet that dissolves under the tongue or inside the cheek. Films often dissolve quickly, are harder to tamper with, and many patients find them convenient.
Common side effects of buprenorphine products are usually manageable, and your clinician can help adjust your plan if they persist. They include:
For a fuller breakdown of what to expect, our guide to Suboxone side effects walks through each one.
More serious risks are uncommon but important. Combining buprenorphine with benzodiazepines or alcohol can cause dangerous respiratory depression, and liver injury is documented in product labeling.
Misuse can include crushing and injecting. Naloxone in Suboxone can precipitate withdrawal if the product is injected, which reduces injection misuse but does not eliminate every diversion route. Clinicians counsel patients to avoid alcohol and benzodiazepines and to monitor sedation and liver tests when indicated.
Choosing the most practical formulation often comes down to misuse risk, how you prefer to take medication, and how easily you can reach follow-up care, whether at a clinic, a mobile site, or a telehealth visit.
Clinicians typically prefer buprenorphine-only (Subutex) in specific situations:
Buprenorphine/naloxone (Suboxone) is preferred for most outpatient treatment to reduce injection-misuse risk.
Switching between products is straightforward with clinician oversight. The plan generally involves reviewing your regimen, timing the change appropriately, and starting the equivalent buprenorphine dose of the new product, with informed consent and any required prior authorization. If you’re moving off methadone, our guide on transitioning from methadone to Suboxone covers what to expect.
For monitoring, you can expect:
A small practical tip helps: sort out paperwork and prior authorization before day one to avoid a prescription-day scramble.
Buprenorphine, with or without naloxone, is used to treat opioid use disorder during pregnancy because treatment lowers the serious harms of continued illicit opioid use. Stopping medication during pregnancy is generally not recommended.
According to ACOG’s guidance on opioid use disorder in pregnancy, the priority is to continue buprenorphine rather than stop it. Buprenorphine-only has historically been preferred, but combination products are not universally contraindicated, and decisions should be individualized with specialist input.
Neonatal opioid withdrawal syndrome (NOWS) can develop after in-utero exposure. Monitoring and supportive, nonpharmacologic care are often enough, with NICU monitoring and symptom-directed treatment reserved for more severe cases.
Breastfeeding is generally encouraged on a stable buprenorphine regimen, because concentrations in breast milk are low and the benefits usually outweigh the risks. Before delivery, coordinate the following so your newborn gets timely support:
Our treatment during pregnancy services help coordinate this care.
What you pay depends on several factors:
Generic buprenorphine and buprenorphine/naloxone are typically the lowest-cost options. Check your plan for prior authorization or step-therapy requirements, and ask clinics about sliding-scale fees, mobile visits, or in-network options, and remember that finding a Suboxone provider that accepts Medicaid can lower your costs further.
A few steps help right now:
We expand access to medically focused MAT across Colorado and New Mexico, so you can start and continue buprenorphine-based care close to home through in-clinic, mobile, and virtual visits.
Clinicians evaluate withdrawal risk, start buprenorphine safely, and schedule close follow-up to limit precipitated withdrawal and track your response. You receive medication plus regular clinical checks and toxicology testing as indicated.
Medication works best paired with counseling. You can access individual and group counseling and behavioral services integrated with MAT, along with practical relapse-prevention planning.
Care teams verify insurance, confirm details like Medicaid coverage for Suboxone, arrange sliding-scale options when available, and use mobile units and telehealth to keep treatment consistent if you move or live in a rural area. Finding a nearby access point often makes the difference between starting treatment and waiting.
Choosing between Subutex and Suboxone is easier with someone in your corner. Whether you’re starting treatment, switching formulations, or helping someone you love, we can walk you through what fits your history, your health, and your insurance.
There’s no pressure here, just a conversation about your next step. Call us at 866-839-8868, or find a Porch Light Health clinic or schedule a virtual visit to get started.
Can naloxone in Suboxone cause harm if I have liver disease or take other medications?
Naloxone in Suboxone is present to discourage injection and has very low sublingual absorption in people with normal liver function, so it generally has no effect when taken as prescribed. Both naloxone and buprenorphine are metabolized in the liver, so dose adjustments or extra monitoring may be needed for severe hepatic impairment.
If you take other medicines that affect liver enzymes or cause sedation, your clinician will check for interactions and may order liver tests before and during treatment. Tell your clinician about all prescription drugs, over-the-counter medicines, herbal products, and alcohol.
If I’m pregnant, should I switch from Suboxone to buprenorphine-only (Subutex)?
Current professional guidance prioritizes continuing buprenorphine treatment during pregnancy rather than stopping, because treatment lowers the risks of untreated opioid use disorder. Buprenorphine-only has often been preferred historically, but combination products are not universally contraindicated, and decisions should be individualized with specialist input.
If you are pregnant or planning pregnancy, discuss options with your clinician so the plan balances maternal stability, neonatal outcomes, and any local prescribing rules.
How soon after my last opioid use can I take my first dose of buprenorphine?
To reduce the risk of precipitated withdrawal, you need to be in at least mild-to-moderate withdrawal before taking buprenorphine. Guidance gives specific wait times based on the opioid used and recommends objective assessment, such as the Clinical Opiate Withdrawal Scale, with clinician supervision.
If you are unsure how long to wait, contact a clinician experienced in inductions so they can evaluate your recent use and help choose a standard induction, microdosing, or a rapid-start approach.
Are buprenorphine films less likely to be diverted than tablets?
Films were developed partly to reduce diversion and tampering compared with older tablets, and some studies report lower tampering rates with films, though no formulation fully prevents diversion. Reviews find similar clinical effectiveness across formulations while noting differences in misuse risk.
Clinicians also use dispensing strategies such as witnessed dosing, take-home limits, and urine drug testing to reduce diversion risk regardless of the form prescribed.
How do I switch from Suboxone to a buprenorphine-only product, and what should my clinician monitor?
Switching generally involves stopping the combination product and starting a buprenorphine-only formulation once you are clinically stable, timing the first dose to mild withdrawal for a standard sublingual induction. Clinicians should document baseline liver tests when indicated, check urine drug screens, and monitor for withdrawal, cravings, sedation, or oversedation, adjusting the dose as needed.
Plan the switch with a clinician who can arrange follow-up, coordinate any prior authorization, and ensure supportive services so the change maintains your safety and continuity of care.
Subutex and Suboxone both rely on buprenorphine. For most people, the real question is not which is universally “better” but which fits your medical history, your pregnancy or liver status, and how you can reliably get follow-up care. A clinician can match the formulation to your situation and arrange the monitoring that keeps treatment safe.
Our team serves Colorado and New Mexico with in-clinic, mobile, and telehealth visits, and can begin treatment quickly when you are ready. To get started, reach out to Porch Light Health or call 866-839-8868.
